Heska Corp (HSKA): Kevin S. Wilson , CEO and President of Heska Corp sold 10,000 shares on May 5, 2016. The Insider selling transaction was reported by the company on May 11, 2016 to the Securities and Exchange Commission. The shares were sold at $35.63 per share for a total value of $356,088.34 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on May 10, 2016, Sharon L. Riley (director) sold 5,000 shares at $36.87 per share price.On May 10, 2016, Michael J Mcginley (Presi, Biologic. & Pharm.) sold 5,998 shares at $36.50 per share price.Also, On May 9, 2016, Kevin S. Wilson (CEO and President) sold 11,000 shares at $35.63 per share price.On May 5, 2016, Jason A Napolitano (COO, CFO, EVP and Secretary) sold 5,000 shares at $35.75 per share price.
Heska Corp: On Tuesday, May 10, 2016 heightened volatility was witnessed in Heska Corp which led to swings in the share price. The shares opened for trading at $36.45 and hit $38.49 on the upside , eventually ending the session at $38.465, with a gain of 5.62% or 2.045 points. The heightened volatility saw the trading volume jump to 1,26,777 shares. The 52-week high of the share price is $40.29 and the company has a market cap of $255 M . The 52-week low of the share price is at $26.255.
Company has been under the radar of several Street Analysts.Heska Corp is Initiated by CL King to Buy. The Rating was issued on Apr 1, 2016.
Heska Corporation develops manufactures markets sells and supports veterinary products. The Company is focused on the canine and feline companion animal health markets. The Company operates in two segments: Core Companion Animal Health and Other Vaccines Pharmaceuticals and Products. The Core Companion Animal Health segment (CCA) includes primarily for canine and feline use blood testing instruments and supplies digital imaging products software and services and single use products and services such as heartworm diagnostic tests heartworm preventive products allergy immunotherapy products and allergy testing. The Other Vaccines Pharmaceuticals and Products segment (OVP) includes private label vaccine and pharmaceutical production primarily for cattle but also for other animals including small mammals.